<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01606371</url>
  </required_header>
  <id_info>
    <org_study_id>10837</org_study_id>
    <secondary_id>I1R-FW-GLBA</secondary_id>
    <nct_id>NCT01606371</nct_id>
  </id_info>
  <brief_title>A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2409021 After Escalating Single Oral Dose Administration in Healthy Subjects and Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the safety of LY2409021 in healthy
      participants and participants with diabetes. The study drug is given as single oral doses.
      Each participant can receive up to 3 doses, with a minimum 7 day washout between dosing
      periods. Side effects will be documented. This study is approximately 9 weeks long, not
      including screening. Screening is required within 6 weeks prior to the start of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with one or more drug related adverse events (AEs) or any serious AEs</measure>
    <time_frame>From first dose of study drug up to discharge (at least 14 days after last dose)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the concentration curve (AUC) of LY2409021</measure>
    <time_frame>From each dose of study drug up to 14 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum concentration (Cmax) of LY2409021</measure>
    <time_frame>From each dose of study drug up to 14 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting blood glucose level</measure>
    <time_frame>From each dose of study drug up to 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting insulin level</measure>
    <time_frame>From each dose of study drug up to 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucagon level</measure>
    <time_frame>From each dose of study drug up to 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucagon-like peptide-1 (GLP-1) level</measure>
    <time_frame>From each dose of study drug up to 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose excursion after meals</measure>
    <time_frame>28 hours after each dose</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Healthy-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (capsule) administered once, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy-2.5 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg LY2409021 administered once, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy-10 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg LY2409021 administered once, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy-30 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg LY2409021 administered once, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy-100 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg LY2409021 administered once, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy-250 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 mg LY2409021 administered once, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy-500 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg LY2409021 administered once, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (capsule) administered once, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic-75 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 mg LY2409021 administered once, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic-200 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg LY2409021 administered once, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic-500 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg LY2409021 administered once, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Healthy-Placebo</arm_group_label>
    <arm_group_label>Diabetic-Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2409021</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Healthy-2.5 mg LY2409021</arm_group_label>
    <arm_group_label>Healthy-10 mg LY2409021</arm_group_label>
    <arm_group_label>Healthy-30 mg LY2409021</arm_group_label>
    <arm_group_label>Healthy-100 mg LY2409021</arm_group_label>
    <arm_group_label>Healthy-250 mg LY2409021</arm_group_label>
    <arm_group_label>Healthy-500 mg LY2409021</arm_group_label>
    <arm_group_label>Diabetic-75 mg LY2409021</arm_group_label>
    <arm_group_label>Diabetic-200 mg LY2409021</arm_group_label>
    <arm_group_label>Diabetic-500 mg LY2409021</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For all participants:

          -  Must be either a male, or a female who cannot become pregnant, who is either healthy
             or have type 2 diabetes mellitus (T2DM) but not taking medication for diabetes

          -  Have an hemoglobin A1c (HbA1c) value of less than or equal to 10% at screening

          -  Have blood and urine laboratory test results that are acceptable for the study

        For healthy participants:

          -  Have a screening body mass index (BMI) of 18.5 to 29.9 kg/m^2 inclusive

          -  Have a fasting blood glucose between 3.0-5.2 millimoles/liter (mmol/L) at screening

          -  Have plasma glucose, two hours after ingesting an oral 75 g glucose load, less than
             7.8 mmol/L

        For participants with type 2 diabetes mellitus (T2DM):

          -  Have a screening body mass index (BMI) of 18.5 to 35 kg/m^2 inclusive

          -  Must weigh 45 kg or more at screening

          -  Have a fasting blood glucose less than 11.1 mmol/L at screening

          -  Have plasma glucose, two hours after ingesting an oral 75 g glucose load, greater than
             or equal to 11.1 mmol/L

        Exclusion Criteria:

        For all participants:

          -  Have participated in a study with a new drug in the last 30 days

          -  Have a history of significant heart, lung, liver, kidney, stomach or brain disease, or
             have any medical problems which may cause an increased risk during the study

          -  Have hypertension requiring more than single-agent therapy, or blood pressure greater
             than 140/90 millimeters of mercury (mmHg) on monotherapy

          -  Are allergic to LY2409021 or similar drugs

          -  Have a regular alcohol intake greater than 21 units/week (male), or 14 units/week
             (female), or are unwilling to stop alcohol as required by the study restrictions (1
             unit = 360 mL of beer, or 150 mL of wine, or 45 mL of spirits)

          -  Intend to use other over-the-counter or prescribed medicines during 7 or 14 days
             respectively before the study, or during the study. Medicines for high cholesterol and
             high blood pressure are allowed if you have diabetes.

          -  Have a significant blood disorder and/or donated blood (450 ml or more) in the last 3
             months

        For participants with T2DM:

          -  Have signs of having serious problems with diabetes (For example, severe eye problems,
             poorly healing skin)

          -  Have a history of being in a coma due to low blood sugar
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-45 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <last_update_submitted>May 23, 2012</last_update_submitted>
  <last_update_submitted_qc>May 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

